Botulinum toxin type A

Generic Name
Botulinum toxin type A
Brand Names
Botox, Botox Cosmetic, Dysport, Jeuveau, Xeomin, Nuceiva
Drug Type
Biotech
Chemical Formula
-
CAS Number
93384-43-1
Unique Ingredient Identifier
0A6JH35GMQ
Background

In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperfections, muscle spasms, and other conditions. A popular use for Botox is the treatment of facial wrinkles and lines, however, there are many uses for the botulinum toxin A in the treatment of dystonia, incontinence, migraine, blepharospasm, and hyperhidrosis.

Indication

Botulinum toxin A is indicated for a variety of conditions, depending on the preparations. Cosmetically, it is used for the treatment of facial fine lines and wrinkles, specifically for upper facial rhytides, including forehead, lateral canthus, and glabellar lines.

In addition to the above indications, botulinum toxin A is used for the following conditions: treatment of adults with symptomatic overactive bladder with or without incontinence, treatment of incontinence in adult patients who are not candidates for anticholinergic therapy, treatment of Neurogenic Detrusor Overactivity (NDO) in patients over 5 years who cannot undergo anticholinergic therapy. Botulinum toxin A is indicated for the prevention of chronic migraines, for the treatment of muscle spasms, cervical dystonia, axillary hyperhidrosis, strabismus, and disorders of the 7th cranial nerve.

Off-label, botulinum toxin A is used for a variety of conditions such as temporomandibular joint (TMJ) disorders and myofascial pain, neurogenic thoracic outlet syndrome, epicondylitis, post-stroke pain, post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, neuropathic pain, spinal cord injury, and bladder pain.

Associated Conditions
Bladder pain, Blepharospasm, Cervical Dystonia, Chronic Migraine, Diabetic Neuropathies, Epicondylitis, Equinus deformity of foot, acquired, Facial Skin Wrinkles, Glabellar Frown Lines (GL), Lower Limb Spasticity, Myofascial Pain Syndrome, Neurogenic Detrusor Overactivity, Neurogenic Thoracic Outlet Syndrome, Overactive Bladder Syndrome (OABS), Post Stroke Pain, Postherpetic Neuralgia, Sialorrhea, Spasticity, Spinal Cord Injuries, Strabismus, TMJ Disorders, Trigeminal Neuralgia (TN), Upper Limb Spasticity, Urinary Incontinence (UI), Hypertonicity disorders of the 7th nerve, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL), Severe axillary hyperhidrosis
Associated Therapies
-

Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study

First Posted Date
2016-09-20
Last Posted Date
2017-10-13
Lead Sponsor
ICLS Dermatology & Plastic Surgery
Target Recruit Count
10
Registration Number
NCT02907268

Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection

Phase 2
Completed
Conditions
Interventions
First Posted Date
2016-09-01
Last Posted Date
2018-01-25
Lead Sponsor
Xijing Hospital
Target Recruit Count
17
Registration Number
NCT02886988
Locations
🇨🇳

Xijing Hospital, Xi'an, Shaanxi, China

A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia

First Posted Date
2016-08-08
Last Posted Date
2022-11-10
Lead Sponsor
Centre Hospitalier Universitaire de Besancon
Target Recruit Count
60
Registration Number
NCT02858219
Locations
🇫🇷

CHU Besançon, Besançon, France

🇫🇷

Hôpital Tenon, Paris, France

Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis

First Posted Date
2016-07-12
Last Posted Date
2016-07-12
Lead Sponsor
Federal University of São Paulo
Target Recruit Count
105
Registration Number
NCT02829281
Locations
🇧🇷

Universidade Federal de Sao Paulo, Sao Paulo, SP, Brazil

Mixed Urinary Incontinence Symptoms Before and After Treatment With Botox and Bulkamid

First Posted Date
2016-06-28
Last Posted Date
2020-03-12
Lead Sponsor
Prof. Dr. Volker Viereck
Target Recruit Count
58
Registration Number
NCT02815046
Locations
🇨🇭

Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland

Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study

First Posted Date
2016-06-22
Last Posted Date
2016-06-22
Lead Sponsor
University of Manitoba
Target Recruit Count
40
Registration Number
NCT02810015

Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia

First Posted Date
2016-05-16
Last Posted Date
2019-08-14
Lead Sponsor
Karolinska Institutet
Target Recruit Count
90
Registration Number
NCT02773641
Locations
🇸🇪

Danderyd Hospital, Dep. of Obstetrics and Gynecology, Stockholm, Sweden

Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients

First Posted Date
2016-04-25
Last Posted Date
2018-07-18
Lead Sponsor
Chang Gung Memorial Hospital
Target Recruit Count
37
Registration Number
NCT02749591
Locations
🇨🇳

Department of Rehabilitation, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan, Kaohsiung, Taiwan

Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury

First Posted Date
2016-04-13
Last Posted Date
2019-04-09
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Target Recruit Count
8
Registration Number
NCT02736890
Locations
🇺🇸

Mount Sinai Hospital, New York, New York, United States

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II

First Posted Date
2016-02-09
Last Posted Date
2022-05-19
Lead Sponsor
Croma-Pharma GmbH
Target Recruit Count
200
Registration Number
NCT02677805
© Copyright 2024. All Rights Reserved by MedPath